A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Phase 2 Completed 130 enrolled VIVUS LLC Sentrx · collab Synteract, Inc. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.

Timeline

Start: 2008-01
Primary completion: 2008-11
Completion: 2008-11

Publications

Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec;37(12):3309-16. doi: 10.2337/dc14-0930. Epub 2014 Sep 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Phentermine	Small molecule	15 mg	Oral
Subject	Topiramate	Small molecule	92 mg	Oral

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Summary

Timeline

Publications

Drugs

Indications